ViiV Releases Promising Phase 2 Data on Potential Long-acting HIV Drugs
Gilead Sciences Presented First Clinical Data For Its Investigational Once-Yearly Lenacapavir For HIV Prevention At CROI 2025 And Published In The Lancet
10 Health Care Stocks Whale Activity In Today's Session
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
Genmab Upgraded to Outperform at William Blair